Latest News

HIV diagnosis at home and same-day ART start tied to better outcomes


 

REPORTING FROM CROI


To see whether same-day ART initiation could be accomplished in the field, Dr. Labhardt and his colleagues designed a multicenter, randomized trial in 278 individuals aged 18 years and older from 268 households. The participants who tested HIV positive and were ART naive were chosen from among 6,655 households in rural villages and 17 urban areas in Lesotho who took part in a home-based testing program.

After giving consent, the participants were randomly assigned to either the same-day or standard of care groups.

In the same-day group, participants were offered home-based ART initiation, given a 1-month supply of drugs, and instructed to visit a specified health facility in 2-4 weeks for their first check-up and refill. The patients were scheduled for additional follow-up visits at 1.5, 3, 6, 9, and 12 months.

In the standard-of-care group, patients received posttest counseling at home and were given an appointment to their nearest health facility within the next 4 weeks; once they were linked to care, they were required to make at least two additional visits for testing prior to starting on ART. Once they started ART, they were given monthly follow-up and drug-refill appointments.

Pages

Recommended Reading

State regulations for tattoo facilities increased blood donor pools
Federal Practitioner
Boston VA Medical Forum: HIV-Positive Veteran With Progressive Visual Changes
Federal Practitioner
Introducing the VA Boston Medical Forum
Federal Practitioner
Monitoring HIV and Kidney Disease in Aging Asians
Federal Practitioner
Reducing the Stigma of HIV Testing With Online Support
Federal Practitioner
Clinical Trial Begins for Long-Acting Anti-HIV Injectable
Federal Practitioner
Closing the Timing Gap Between HIV Infection and Diagnosis
Federal Practitioner
HIV Treatment: OK to Take a Break?
Federal Practitioner
Large-vessel vasculitis: More severe in HIV-infected patients
Federal Practitioner
Inflammatory markers predict vaccine response in HCV, HIV
Federal Practitioner